Navigation Links
Overcoming the IVF baby blues
Date:11/9/2010

Between 20 and 30 percent of women who undergo in vitro fertilization (IVF) procedures suffer from significant symptoms of depression. Many practitioners believe that the hormone therapy involved in IVF procedures is primarily responsible for this. But new research from Tel Aviv University shows that, while this is true, other factors are even more influential.

According to Dr. Miki Bloch of Tel Aviv University's Sackler Faculty of Medicine and the Sourasky Medical Center in Tel Aviv, stress, pre-existing depression, and anxiety are more likely than hormone therapy to impact a woman's depression levels when undergoing IVF. Combined, these factors may also affect IVF success rates ― so diagnosis and treatment of this depression is very important.

Recently reported in the Journal of Fertility and Sterility, Dr. Bloch's research clarifies the involvement of different hormonal states as triggers for depression during IVF, both for long- and short-term protocols.

The long and short stories

In the long-term IVF protocol, explains Dr. Bloch, women receive injections which block ovulation, resulting in a sharp decline in estrogen and progesterone levels. This state continues for a two-week period before the patient is injected with hormones to stimulate ovulation, at which point the eggs are harvested and fertilized before being replanted into the womb. The short-term IVF protocol, on the other hand, does not include the initial two-week period of induction of a low hormonal state.

Some gynaecologists believe that depression is more likely when a woman undergoes long-term IVF therapy because of those first two weeks of hormonal repression. But Dr. Bloch's research has demonstrated that the difference between the two different procedures is negligible ― depression and anxiety rates for women who undergo the long protocol and those who undergo the short are exactly the same.

Dr. Bloch and his fellow researchers conducted a random assignment study, in which 108 women who came to the Sourasky Medical Center for IVF were randomly assigned to either the long- or short-term protocol. They were given questionnaires and interviews at the start of the therapy and at four other points during the IVF treatment.

The results, says Dr. Bloch, show consistently increasing depression rates among patients in both groups, irrespective of which protocol they underwent. The first two weeks of hormonal repression, he explains, thus have no impact on whether a woman experiences depression during IVF. "Once the patient begins ovulating, her estrogen rises to high levels. Then, after the ovum is replanted in her uterus, there is a precipitous drop in these hormonal levels," he explains. It's the severity of the estrogen drop, a feature of both protocols, that was found to affect the patient's emotional state.

Preventing stress in susceptible women

Whatever the specific effect of hormones, during their study Dr. Bloch and his fellow researchers discovered that the stress and anxiety experienced during the treatment has a significant impact on patient depression rates. When compared to a "normal" population, women undergoing IVF experience very high levels of anxiety and depression even before the treatment begins. As the protocol advances, explains Dr. Bloch, women experience increased anxiety about the success of the implantation.

Women who have a previous history of anxiety or depression disorders before the IVF treatment are even more susceptible, he says. This is likely due to the fact that these women are more emotionally vulnerable to the toll of the IVF process rather then increased reactivity to changing hormonal levels, Dr. Bloch says.

Choosing the right protocol

When it comes to depression rates, the type of protocol a patient undergoes, whether short-term or long-term, has no impact, Dr. Bloch concluded. The combination of the stress surrounding the treatment, a personal history of psychiatric disorders, and a sharp decline in estrogen levels are the main contributing factors towards depression during IVF therapy. While doctors should look at their patient's individual needs when deciding on an IVF protocol, the current report suggests the type of protocol per se is not an important factor in the induction of depression.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Related biology news :

1. Overcoming anthrax bacteriums natural defenses could hold key to new treatments
2. Overcoming Taboos, Myths, and Dogmas in Bioethics
3. More than just the baby blues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... -- ATCC, the premier global biological materials resource and ... life science researchers that are working to address the ... CDC website . --> CDC website ... single-stranded RNA virus of the Flaviviridae family, genus Flavivirus, ... Viruses. Zika virus is transmitted to humans primarily through ...
(Date:2/5/2016)... , February 5, 2016 ... a biotechnology company focused on developing products for Regenerative ... requested Rare Pediatric Disease Designation (RPDD) from the US ... (RP) with MANF. MANF was previously granted orphan drug ... --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... February 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016 ... July 22, 2016   - Lifitegrast ... past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in the past ...
(Date:2/4/2016)... , ... February 04, 2016 ... ... presented by Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at ... event features 20+ speakers and activities such as workshops and competitions for ...
Breaking Biology Technology: